MedTrace Logo

Study of Erenumab (AMG 334) in Women With Hot Flashes

NCT01890109 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2019-01-14

Study results available
· View outcomes & findings →

Summary

The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.

Conditions

  • Vasomotor Symptoms; Hot Flashes

Interventions

BIOLOGICAL

Erenumab

Administered via subcutaneous injection.

DRUG

Placebo

Administered via subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-13
Primary Completion
2014-03-11
Completion
2014-03-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01890109 on ClinicalTrials.gov